# US 2024/0197775 A1 · Compositions and methods for the prevention or treatment of rheumatoid arthritis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197775 A1
- Document ID: US20240197775A1
- Status: Published application
- Kind: A1
- Application number: 18/285,649
- Filed: 2022-04-04
- Published: 2024-06-20
- Earliest claimed: 2021-04-05
- Assignees: Rhode Island Hospital
- Applicants: Rhode Island Hospital
- Inventors: Olin Liang; Eui-Young So; Anthony Reginato
- Web page: https://patentgrep.com/patent/US20240197775A1

## CPC

- A61K 35/15: Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 40/10: characterised by the cell type used
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 37/00: Drugs for immunological or allergic disorders
- C12N 5/0634: {Cells from the blood or the immune system}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C12N 2501/73: Hydrolases (EC 3.)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are compositions and methods for the prevention or treatment of rheumatoid arthritis (RA). In some embodiments, RA is prevented or treated by (i) extracting peripheral blood mononuclear cells (PBMCs) and/or bone marrow mononuclear cells (BMMCs) from a subject at risk of, or afflicted with, RA; (ii) exposing the PBMCs/BMMCs to an effective amount of one or more SHIP-1 inhibitor and/or a pan-SHIP1/2 inhibitor to induce ex vivo expansion of the subject's myeloid derived suppressor cells (MDSCs); and (iii) administering intravenously to the subject a therapeutically effective number of MDSCs.

## Claims

### Claim 1

A method of preventing and/or treating rheumatoid arthritis (RA) in a subject at risk for, or afflicted with, RA comprising the steps of:
(i) extracting peripheral blood mononuclear cells (PBMCs) or bone marrow mononuclear cells (BMMCs) from the subject;
(ii) exposing the PBMCs/BMMCs to an effective amount of one or more SHIP1 inhibitor to induce ex vivo expansion of the subject's myeloid derived suppressor cells (MDSCs); and
(iii) administering intravenously to the subject a therapeutically effective number of MDSCs.

### Claim 2 (depends on 1)

The method of claim 1, wherein the one or more SHIP1 inhibitor is a selective SHIP-1 inhibitor and/or a pan-SHIP1/2 inhibitor, or functionally-equivalent analogs thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the selective SHIP-1 inhibitor is 3α-aminocholestane (3AC).

### Claim 4 (depends on 2)

The method of claim 2, wherein the pan-SHIP1/2 inhibitor is selected from the group consisting of: Compound 26, Compound 27, Compound 28, K116, K118, K149, K161, and AS194490.

### Claim at position 5

5-8. (canceled)
